These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33879100)

  • 1. Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer.
    Sugiura K; Seo Y; Takahashi T; Tokura H; Ito Y; Tanaka M; Kishida N; Nishi Y; Onishi Y; Aoki H
    BMC Gastroenterol; 2021 Apr; 21(1):184. PubMed ID: 33879100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States.
    Cho SK; Hay JW; Barzi A
    Clin Colorectal Cancer; 2018 Dec; 17(4):e751-e761. PubMed ID: 30228027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
    Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis.
    Zhu Y; Liu K; Zhu H
    Therap Adv Gastroenterol; 2024; 17():17562848241284998. PubMed ID: 39372041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two Cases of Metastatic Colorectal Cancer Treated with TAS-102 plus Bevacizumab].
    Maeda F; Gan S; Yamada A; Kajiyama D; Tokitou F; Kawaguchi M; Amagasa H; Motoyama K; Ganno H; Imai K; Ami K; Iida S; Fukuda A; Ando M; Okano Y
    Gan To Kagaku Ryoho; 2021 Mar; 48(3):419-421. PubMed ID: 33790174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
    Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
    Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
    Fujii H; Matsuhashi N; Kitahora M; Takahashi T; Hirose C; Iihara H; Yamada Y; Watanabe D; Ishihara T; Suzuki A; Yoshida K
    Oncologist; 2020 Mar; 25(3):e469-e476. PubMed ID: 32162797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):e6904. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of pembrolizumab in patients with treatment-refractory metastatic colorectal cancer in Japan.
    Sugiura K; Hiratsuka H; Oshima G; Aiko S
    Jpn J Clin Oncol; 2023 Jul; 53(8):691-697. PubMed ID: 37259600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
    Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
    Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
    Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
    Naito A; Iwamoto K; Ohtsuka M; Imasato M; Inui M; Zenitani S; Wada R; Nakahara Y; Mikamori M; Furukawa K; Moon J; Asaoka T; Kishi K; Akamatsu H
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2104-2106. PubMed ID: 33468875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
    Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
    Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
    Giuliani J
    Clin Colorectal Cancer; 2022 Jun; 21(2):e145-e147. PubMed ID: 34969632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.